Fig. 4

Influence of eiF4F inhibitors on PCa cells. A Schematic representation of the therapeutic target structures of Briciclib (eIF4E-inhibitor), Rocaglamide (Roca, eiF4A-inhibitor), and SBI-0640756 (eIF4G1-inhibitor) on the Eif4F complex. Created By Biorender. B Representative Western Blot of eiF4A, eiF4E, eiFG1, and total protein stain (TPS) of LNCaP, C4-2, 22Rv1 cells. Uncropped western blots are displayed in Supplementary Fig. 6, C Densitometry of eiF4A, eiF4E, and eiFG1 relative to TPS. Data is shown as box and whisker (min to max) of five independent western blot experiments. D Dose–response curves of change in cell proliferation after treatment with different concentrations of Briciclib, Rocaglamide, and SBI-0640756 of LNCaP, C4-2, 22Rv1 cells after 72 h. Data was plotted as mean ± SEM of the three biological replicates. E Dose–response curves of change in cell proliferation after treatment with different concentrations of Briciclib, Rocaglamide, and SBI-0640756 of LNCaP, C4-2, 22Rv1 cells after 6 h. Data was plotted as mean ± SEM of the three biological replicates